Trial Summary
An estimated 86 client-owned pet dogs will be enrolled in this Phase II study. The study is a randomized, investigator-masked, placebo-controlled study in dogs with measurable soft tissue sarcoma. The randomization of active Test Article to placebo will be 1:1 with a crossover option for dogs in the placebo arm that have disease progression.
The first eight (8) dogs enrolled in the study will be assigned to receive active Test Article in an open label manner and will have blood samples collected over a period of 24 hours post treatment.
Once enrolled, study patients will be evaluated at Days 14, 28 and every 28 days thereafter until tumor progression occurs.
Trial Support and Funding
Study drug, diagnostic tests, and follow-up exams will be paid for by the study sponsor. In the event that side effects are noted and attributed to the study drug, the study will pay for medical management of the side effects.
For more information please fee free to post comments, ask questions, or visit animalci.com 
An estimated 86 client-owned pet dogs will be enrolled in this Phase II study. The study is a randomized, investigator-masked, placebo-controlled study in dogs with measurable soft tissue sarcoma. The randomization of active Test Article to placebo will be 1:1 with a crossover option for dogs in the placebo arm that have disease progression.
The first eight (8) dogs enrolled in the study will be assigned to receive active Test Article in an open label manner and will have blood samples collected over a period of 24 hours post treatment.
Once enrolled, study patients will be evaluated at Days 14, 28 and every 28 days thereafter until tumor progression occurs.
Trial Support and Funding
Study drug, diagnostic tests, and follow-up exams will be paid for by the study sponsor. In the event that side effects are noted and attributed to the study drug, the study will pay for medical management of the side effects.